| Ident. | Authors (with country if any) | Title |
|---|
| 000200 |
Cleide Lopes [Brésil] ; Andrea M. Esteves [Brésil] ; Roberto Frussa-Filho [Brésil] ; Sergio Tufik [Brésil] ; Marco Tulio De Mello [Brésil] | Evaluation of Periodic Limb Movements in a Putative Animal Model of Restless Leg Syndrome |
| 000383 |
Christopher Kobylecki [Royaume-Uni] ; Michael P. Hill [Canada] ; Alan R. Crossman [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni, Canada] | Synergistic Antidyskinetic Effects of Topiramate and Amantadine in Animal Models of Parkinson's Disease |
| 000488 |
Benjamin Dehay [France] ; Erwan Bezard [France] | New Animal Models of Parkinson's Disease |
| 000591 |
ZHENYU YUE [États-Unis] ; M. Lenard Lachenmayer [États-Unis, Allemagne] | Genetic LRRK2 Models of Parkinson's Disease: Dissecting the Pathogenic Pathway and Exploring Clinical Applications |
| 000614 |
Martin Köllensperger [Autriche] ; Florian Krismer [Autriche] ; Anton Pallua [Autriche] ; Nadia Stefanova [Autriche] ; Werner Poewe [Autriche] ; Greqor K. Wenning [Autriche] | Erythropoietin is Neuroprotective in a Transgenic Mouse Model of Multiple System Atrophy |
| 000731 |
Erwan Bezard [France] ; Serge Przedborski [États-Unis] | A Tale on Animal Models of Parkinson's Disease |
| 000994 |
Hans C. Scholle [Allemagne] ; H. A. Jinnah [États-Unis] ; Dirk Arnold [Allemagne] ; Frank H. W. Biedermann [Allemagne] ; Bernd Faenger [Allemagne] ; Roland Grassme [Allemagne] ; Ellen J. Hess [États-Unis] ; Nikolaus P. Schumann [Allemagne] | Kinematic and Electromyographic Tools for Characterizing Movement Disorders in Mice |
| 000A70 |
Marta G. Vuckovic [États-Unis] ; QUANZHENG LI [États-Unis] ; Beth Fisher [États-Unis] ; Angelo Nacca [États-Unis] ; Richard M. Leahy [États-Unis] ; John P. Walsh [États-Unis] ; Jogesh Mukherjee [États-Unis] ; Celia Williams [États-Unis] ; Michael W. Jakowec [États-Unis] ; Giselle M. Petzinger [États-Unis] | Exercise Elevates Dopamine D2 Receptor in a Mouse Model of Parkinson's Disease: In Vivo Imaging with [18F]Fallypride |
| 000A81 |
Giselle M. Petzinger [États-Unis] ; Beth E. Fisher [États-Unis] ; Jon-Eric Van Leeuwen [États-Unis] ; Marta Vukovic [États-Unis] ; Gamik Akopian [États-Unis] ; Charlie K. Meshul [États-Unis] ; Daniel P. Holschneider [États-Unis] ; Angelo Nacca [États-Unis] ; John P. Walsh [États-Unis] ; Michael W. Jakowec [États-Unis] | Enhancing Neuroplasticity in the Basal Ganglia: The Role of Exercise in Parkinson's Disease |
| 001272 |
Kunal Chaniary [États-Unis] ; Mark Baron [États-Unis] ; Ann Rice [États-Unis] ; Paul Wetzel [États-Unis] ; Steven Shapiro [États-Unis] | Electromyographic Characterization in an Animal Model of Dystonia |
| 001493 |
Vincent Paille [France] ; Vincent Henry [France] ; Laurent Lescaudron [France] ; Philippe Brachet [France] ; Philippe Damier [France] | Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias |
| 001510 |
Anne M. Landau [Canada] ; Edouard Kouassi [Canada] ; Rosmarie Siegrist-Johnstone [Canada] ; Julie Desbarats [Canada] | Proteasome inhibitor model of Parkinson's disease in mice is confounded by neurotoxicity of the ethanol vehicle |
| 001571 |
Anna L. Bartels [Pays-Bas] ; Klaus L. Leenders [Pays-Bas] | Neuroinflammation in the pathophysiology of parkinson's disease : Evidence from animal models to human in vivo studies with [11C]-PK11195 PET |
| 001608 |
Martin Kollensperger [Autriche] ; Nadia Stefanova [Autriche] ; Markus Reindl [Autriche] ; Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche] | Loss of dopaminergic responsiveness in a double lesion rat model of the parkinson variant of multiple system atrophy |
| 001863 |
Susan H. Fox [Canada] ; Anthony E. Lang [Canada] ; Jonathan M. Brotchie [Canada] | Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies : Keys to success and roads to failure |
| 001966 |
Naomi P. Visanji [Canada] ; Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Donna Pires [Canada] ; Valerie Voon [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease |
| 001B97 |
Fredricka C. Martin [États-Unis] ; Adrian Handforth [États-Unis] | Carbenoxolone and mefloquine suppress tremor in the harmaline mouse model of essential tremor |
| 002011 |
H. A. Jinnah [États-Unis] ; Ellen J. Hess [États-Unis] ; Mark S. Ledoux [États-Unis] ; Nutan Sharma [États-Unis] ; Mark G. Baxter [Royaume-Uni] ; Mahlon R. Delong [États-Unis] | Rodent models for dystonia research : Characteristics, evaluation, and utility |
| 002391 |
Michael P. Hill [Royaume-Uni] ; Erwan Bezard [France] ; Steven G. Mcguire [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Ann Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique] | Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset |
| 002465 |
Kathy Steece-Collier [États-Unis] ; Timothy J. Collier [États-Unis] ; Paul D. Danielson [États-Unis] ; Roger Kurlan [États-Unis] ; David M. Yurek [États-Unis] ; John R. Jr Sladek [États-Unis] | Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in Parkinsonian rats |
| 002471 |
Gregorio Segovia [Royaume-Uni, Espagne] ; Francisco Mora [Espagne] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease |
| 002590 |
Rebecka Klintenberg [Suède] ; Lars Gunne [Suède] ; Per E. Andren [Suède] | Tardive dyskinesia model in the common marmoset |
| 002601 |
Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Michael Hill [Royaume-Uni] ; Alan Crossman [Royaume-Uni] ; Jonathan Brotchie [Royaume-Uni] | Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease |
| 002621 |
Johannes Schiefer [Allemagne] ; G. Bernhard Landwehrmeyer [Allemagne] ; Hans-Gerd Lüesse [Allemagne] ; Arne Sprünken [Allemagne] ; Christiane Puls [Allemagne] ; Anna Milkereit [Allemagne] ; Eva Milkereit [Allemagne] ; Christoph M. Kosinski [Allemagne] | Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease |
| 002662 |
Alfredo Berardelli [Italie] ; Antonio Curra [Italie] | Pathophysiology and treatment of cranial dystonia |
| 002710 |
Marie-Paule Muriel [France] ; Gaël Orieux [France] ; Etienne C. Hirsch [France] | Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in Parkinsonian rats |
| 002840 |
Dipankar Nandi [Royaume-Uni] ; Tipu Z. Aziz [Royaume-Uni] ; XUGUANG LIU [Royaume-Uni] ; John F. Stein [Royaume-Uni] | Brainstem motor loops in the control of movement |
| 002841 |
Peter J. Healy [Australie] ; Kerrie D. Pierce [Australie] ; Julie A. Dennis [Australie] ; Peter A. Windsor [Australie] ; Peter R. Schofield [Australie] | Bovine myoclonus: Model of human hyperekplexia (Startle disease) |
| 002851 |
Mikko Kuoppam Ki [Royaume-Uni] ; Ghassan Al-Barghouthy [Royaume-Uni] ; Michael Jackson [Royaume-Uni] ; Lance Smith [Royaume-Uni] ; Bai-Yun Zeng [Royaume-Uni] ; Niall Quinn [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa |
| 002896 |
Adrian Handforth [États-Unis] ; Scott E. Krahl [États-Unis] | Suppression of harmaline-induced tremor in rats by vagus nerve stimulation |
| 002916 |
G. M. Petzinger [États-Unis] ; M. Quik [États-Unis] ; E. Ivashina [États-Unis] ; M. W. Jakowec [États-Unis] ; M. Jakubiak [États-Unis] ; D. Di Monte [États-Unis] ; J. W. Langston [États-Unis] | Reliability and validity of a new global dyskinesia rating scale in the MPTP-lesioned non-human primate |
| 002944 |
R. E. Yee [États-Unis] ; I. Irwin [États-Unis] ; C. Milonas [États-Unis] ; D. B. Stout [États-Unis] ; S-C. Huang [États-Unis] ; K. Shoghi-Jadid [États-Unis] ; N. Satyamurthy [États-Unis] ; L. E. Delanney [États-Unis] ; D. M. Togasaki [États-Unis] ; K. F. Farahani [États-Unis] ; K. Delfani [États-Unis] ; A. M. Janson [États-Unis] ; M. E. Phelps [États-Unis] ; J. W. Langston [États-Unis] ; J. R. Barrio [États-Unis] | Novel observations with FDOPA-PET imaging after early nigrostriatal damage |
| 002952 |
Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Micheal P. Hill [Royaume-Uni] ; David Peggs [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct : Evidence from the effects of the Alpha2 adrenoceptor antagonist idazoxan |
| 002A36 |
Krishna P. Datla [Royaume-Uni] ; Stavia B. Blunt [Royaume-Uni] ; David T. Dexter [Royaume-Uni] | Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl3 nigrostriatal lesions |
| 002A41 |
Hélène Turmel [France] ; Andreas Hartmann [France] ; Karine Parain [France] ; Aicha Doubou [France] ; Anu Srinivasan [États-Unis] ; Yves Agid [France] ; Etienne C. Hirsch [France] | Caspase-3 activation in 1 -methyl-4-phenyl- 1, 2,3,6-tetrahydropyridine (MPTP)-treated mice |
| 002A60 |
Eleni C. Maratos [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Ronald K. B. Pearce [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus) |
| 002A90 |
I. Ghorayeb [France] ; P. O. Fernagut [France] ; I. Aubert [France] ; E. Bezard [France] ; Werner Poewe [Autriche] ; G. K. Wenning [Autriche] ; F. Tison [France] | Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration |
| 002B26 |
D. A. Di Monte [États-Unis] ; A. Mccormack [États-Unis, Suède] ; G. Petzinger [États-Unis] ; A. M. Janson [États-Unis, Suède] ; M. Quik [États-Unis] ; W. J. Langston [États-Unis] | Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model |
| 002B40 |
C. G. Goetz [États-Unis] ; T. Q. Vu ; P. M. Carvey ; S. Leurgans | Posthypoxic myoclonus in the rat : Natural history, stability, and serotonergic influences |
| 002C35 |
W. G. Ondo [États-Unis] ; YI HE [États-Unis] ; S. Rajasekaran [États-Unis] ; W.-D. Le [États-Unis] | Clinical correlates of 6-hydroxydopamine injections into all dopaminergic neurons in rats : A possible model for restless legs syndrome? |
| 002C43 |
H. A. Jinnah [États-Unis] ; J. P. Sepkuty [États-Unis] ; T. Ho [États-Unis] ; S. Yitta [États-Unis] ; T. Drew [États-Unis] ; J. D. Rothstein [États-Unis] ; E. J. Hess [États-Unis] | Calcium channel agonists and dystonia in the mouse |
| 002C60 |
D. D. Truong [États-Unis] ; A. Kanthasamy [États-Unis] ; BANG NGUYEN [États-Unis] ; R. Matsumoto [États-Unis] ; P. Schwartz [États-Unis] | Animal models of posthypoxic myoclonus : I. Development and validation |
| 002C61 |
B. Q. Nguyen [États-Unis] ; A. G. Kanthasamy [États-Unis] ; D. D. Truong [États-Unis] | Animal models of myoclonus : An overview |
| 002C62 |
A. G. Kanthasamy [États-Unis] ; B. Q. Nguyen ; D. D. Truong | Animal model of posthypoxic myoclonus : II. Neurochemical, pathologic, and pharmacologic characterization |
| 002D01 |
B. Henry [Royaume-Uni] ; S. H. Fox [Royaume-Uni] ; D. Peggs [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; J. M. Brotchie [Royaume-Uni] | The α2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-Parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease |
| 002D79 |
K. S. Topp [États-Unis] ; N. N. Byl [États-Unis] | Movement dysfunction following repetitive hand opening and closing : Anatomical analysis in owl monkeys |
| 002E65 |
E. Grünblatt [Israël] ; S. Mandel [Israël] ; T. Berkuzki [Israël] ; M. B. H. Youdim [Israël] | Apomorphine protects against MPTP-induced neurotoxicity in mice |
| 002E68 |
H. Wilms [Allemagne] ; J. Sievers [Allemagne] ; G. Deuschl [Allemagne] | Animal models of tremor |
| 002F35 |
M. Gernert [Allemagne] ; A. Richter [Allemagne] ; C. Rundfeldt [Allemagne] ; W. Löscher [Allemagne] | Quantitative EEG analysis of depth electrode recordings fron several brain regions of mutant hamsters with paroxysmal dystonia discloses frequency changes in the basal ganglia |
| 002F42 |
UN JUNG KANG [États-Unis] | Potential of gene therapy for Parkinson's disease : Neurobiologic issues and new developments in gene transfer methodologies |
| 002F49 |
H. Bergman [Israël] ; A. Raz [Israël] ; A. Feingold [Israël] ; A. Nini [Israël] ; I. Nelken [Israël] ; D. Hansel [France] ; H. Ben-Pazi [Israël] ; A. Reches [Israël] | Physiology of MPTP tremor |
| 002F79 |
S. Przedborski [États-Unis] ; V. Jackson-Lewis [États-Unis] | Mechanisms of MPTP toxicity |
| 003083 |
R. J. Elble [États-Unis] | Animal models of action tremor |
| 003085 |
P. J. Blanchet [États-Unis] ; S. Konitsiotis [États-Unis] ; T. N. Chase [États-Unis] | Amantadine reduces levodopa-induced dyskinesias in Parkinsonian monkeys |
| 003095 |
P. A. Lapchak [États-Unis] | A preclinical development strategy designed to optimize the use of glial cell line-derived neurotrophic factor in the treatment of Parkinson's disease |
| 003130 |
M. Jaber [États-Unis] ; S. Jones ; B. Giros ; M. G. Caron | The dopamine transporter : A crucial component regulating dopamine transmission |
| 003198 |
G. Dziewczapolski [Argentine] ; L. B. Menalled [Argentine] ; M. T. Savino [Argentine] ; M. Mora [Argentine] ; F. J. E. Stefano [Argentine] ; O. Gershanik [Argentine] | Mechanism of action of clozapine-induced modification of motor behavior in an animal model of the "super-off" phenomenon |
| 003290 |
J. Wissel [Autriche] ; B. Harlizuis [Allemagne] ; A. Richter [Allemagne] ; W. Löscher [Allemagne] ; L. Schelosky [Allemagne] ; U. Scholz [Allemagne] ; Werner Poewe [Autriche] | A new tremor mutant in the Pietrain pig : An animal model of orthostatic tremor? Clinical and neurophysiological observations |
| 003324 |
G. K. Wenning [Royaume-Uni] ; R. Granata [Italie] ; P. M. Laboyrie [Royaume-Uni] ; N. P. Quinn [Royaume-Uni] ; P. Jenner [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] | Reversal of behavioural abnormalities by fetal allografts in a novel rat model of striatonigral degeneration |
| 003339 |
B.-Y. Zeng [Royaume-Uni] ; P. Jenner [Royaume-Uni] ; C. D. Marsden | Partial reversal of increased preproenkephalin messenger ribonucleic acid (mRNA) and decreased preprotachylikin mRNA by foetal dopamine cells in unilateral 6-hydroxydopamine-lesioned rat striatum parallels functional recovery |
| 003379 |
P. J. Blanchet [Canada] ; R. Grondin ; P. J. Bedard | Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates |
| 003413 |
L. Smith [Royaume-Uni] ; M. De Salvia [Royaume-Uni] ; P. Jenner [Royaume-Uni] ; C. D. Marsden | An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets |
| 003494 |
W. Löscher [Allemagne] ; T. Blanke [Allemagne] ; A. Richter [Allemagne] ; H.-O. Hoppen | Gonadal sex hormones and dystonia : experimental studies in genetically dystonic hamsters |
| 003502 |
R. R. Matsumoto [États-Unis] ; M. J. Hussong ; D. D. Truong | Effects of selective serotonergic ligands on posthypoxic audiogenic myoclonus |
| 003512 |
R. K. B. Pearce [Royaume-Uni] ; M. Jackson [Royaume-Uni] ; L. Smith [Royaume-Uni] ; P. Jenner ; C. D. Marsden | Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus) |
| 003564 |
R. J. Vermeulen [Pays-Bas] ; B. Drukarch [Pays-Bas] ; M. C. R. Sahadat ; C. Goosen ; E. C. Wolters [Pays-Bas] ; J. C. Stoof [Pays-Bas] | The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys |
| 003592 |
D. D. Truong [États-Unis] ; R. R. Matsumoto [États-Unis] ; P. H. Schwartz [États-Unis] ; M. J. Hussong [États-Unis] ; C. G. Wasterlain | Novel rat cardiac arrest model of posthypoxic myoclonus |
| 003595 |
J. D. Belluzzi [États-Unis] ; E. F. Domino ; J. M. May ; K. S. Bankiewicz ; D. A. Mcafee | N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease |
| 003610 |
G. E. Borodic [États-Unis] ; R. Ferrante ; L. Bruce Pearce ; K. Smith [États-Unis] | Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections |
| 003669 |
A. J. Stoessl [Canada] ; E. Polanski ; H. Frydryszak | The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia |
| 003685 |
C. A. Hubbard [États-Unis] ; J. M. Trugman | Reversal of reserpine-induced catalepsy by selective D1 and D2 dopamine agonists |
| 003708 |
K. T. Finnegan [États-Unis] | Neurotoxins and monoamine oxidase inhibition: new aspects |
| 003779 |
I. J. Mitchell [Royaume-Uni] ; A. R. Crossman ; U. Liminga ; P. Andren ; L. M. Gunne | Regional changes in 2-deoxyglucose uptake associated with neuroleptic-induced tardive dyskinesia in the cebus monkey |
| 003984 |
W. Löscher ; J. E. Jr Fisher ; D. Schmidt ; G. Fredow ; D. Hönack ; W. B. Iturrian | The sz mutant hamster: a genetic model of epilepsy or of paroxysmal dystonia? |
| 003A33 |
A. B. Scott ; D. Suzuki | Systemic toxicity of botulinum toxin by intramuscular injection in the monkey |
| 003A68 |
J. G. De Yebenes ; S. Fahn ; V. Jackson-Lewis ; M.-A. Mena | The effect of intracerebroventricular infusion of (+)-4-propyl-9-hydroxynapthoxacine (PHNO) through a totally implanted drug delivery system in rats with dopamine deficiency |
